Loading...
 

Volume 33, Issue 1, March 2022



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2022;33(1):1-6
B Cell Depletion Treatment in Resistant Systemic Sclerosis Interstitial Lung Disease
Authors Information

1Division of Rheumatology, Patras University Hospital, Rion, Patras, Greece

2Department of Internal Medicine, University of Patras Medical School, Rion, Patras, Greece

Abstract

Systemic sclerosis is a systemic, autoimmune disease that in many patients affects not only the skin, but also internal organs, mainly the lung. It is clear that internal organ (ie, lung) involvement determines the prognosis. Therefore, there is an unmet need to introduce novel and more effective treatments capable of halting disease progression and hence improve prognosis.

Experimental data over the past decade has accumulated pointing to the B cell as a player in disease pathogenesis. Consequently, a number of controlled and uncontrolled studies have investigated the results of B cell depletion treatment in patients with SSc. The results are preliminary still encouraging for skin as well as for pulmonary involvement. In this review we will analyse and discuss such trials that have currently added B cell depletion as an alternative promising treatment for resistant interstitial lung disease in scleroderma.


Cite this article as: CA Bounia, S-NC Liossis. B Cell Depletion Treatment in Resistant Systemic Sclerosis Interstitial Lung Disease. Mediterr J Rheumatol 2022;31(1):1-6.

Article Submitted: 4 Apr 2021; Revised Form: 29 Oct 2021; Article Accepted: 15 Nov 2021; Available Online: 31 Mar 2022

 

https://doi.org/10.31138/mjr.33.1.1

This work is licensed under a Creative Commons Attribution 4.0 International License (CC-BY).

©CA Bounia, S-NC Liossis.